Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients.

about

Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients.

Item

http://www.wikidata.org/entity/Q50973325

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@en

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@nl

type

Item

label

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@en

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@nl

prefLabel

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@en

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@nl

P1476

Plasma alpha-1-acid glycoprote ...... xel in breast cancer patients.

@en

P2093

Gwo Fuang Ho

http://www.w3.org/2001/XMLSchema#string

Muhammad Azrif Bin Ahmad Annuar

http://www.w3.org/2001/XMLSchema#string

Rafid Salim Jabir

http://www.w3.org/2001/XMLSchema#string

P2860

Human alpha-1-glycoprotein and its interactions with drugs.

The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

Clinical pharmacokinetics of docetaxel : recent developments.

Clinical pharmacodynamic factors in docetaxel toxicity.

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.

Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.

Relationship of systemic exposure to unbound docetaxel and neutropenia.

P304

142-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1354750X.2017.1334152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

J Stanslas

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28554261

http://www.w3.org/2001/XMLSchema#string